Drug Details

General Information of the Drug (ID: DR7091)
Name
Doxycycline
Synonyms
doxycycline; Vibramycin; 564-25-0; Doxytetracycline; Doxiciclina; Doxycyclinum; Doxycycline (anhydrous); Monodox; Oracea; Vibra-tabs; Doxycycline hyclate; 6alpha-Deoxy-5-oxytetracycline; 5-Hydroxy-alpha-6-deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; Doxycyclin; alpha-6-Deoxy-5-hydroxytetracycline; BMY-28689; Doxycycline anhydrous; Liviatin; DOXY; Doxy-Caps; Vibravenos; UNII-334895S862; Deoxymykoin; Dossiciclina; Azudoxat; Doxitard; Doxivetin; Doxycen; Doxychel; Investin; Ronaxan; CHEBI:50845; Spanor; Doxy-Puren; alpha-Doxycycline; Doxy-Tabs; alpha-6-Deoxyoxytetracycline; MMV000011; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Supracyclin; Doxysol; Jenacyclin; 6-Deoxyoxytetracycline; Dossiciclina [DCIT]; Doxiciclina [Italian]; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; GS-3065; Doxycyclinum [INN-Latin]; Doxycycline (internal use); Doxiciclina [INN-Spanish]; 334895S862; BU-3839T; 4-Epidoxycycline; Zenavod; DOXCYCLINE ANHYDROUS; Oxytetracycline, 6-deoxy-; Doxycycline (TN); Doxychel (TN); (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Vivox (*Hyclate); Doxycycline (INN); DMSC (*Fosfatex); NSC633557; HSDB 3071; Monodox (*monohydrate); BMY28689; BU 3839T; EINECS 209-271-1; BMY 28689; Vibramycin (*monohydrate); GS-3065 (*monohydrate); Doxirobe; Doxycycline [USAN:INN:BAN]; SR-01000075844; Anhydrous doxycycline; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-; AB08 (*Fosfatex); Spectrum_000807; 24390-14-5; Spectrum2_000143; Spectrum3_000408; Spectrum4_000527; Spectrum5_000947; UPCMLD-DP021; CHEMBL1433; Lopac0_000405; SCHEMBL40930; SCHEMBL66828; BSPBio_001936; KBioGR_001133; KBioSS_001287; BIDD:GT0146; DivK1c_000345; SPBio_000246; CHEMBL436921; GTPL6464; SCHEMBL1176275; 4-Epioxytetracycline, 6-deoxy-; DTXSID0037653; SCHEMBL17826665; SCHEMBL19270298; SCHEMBL21753474; UPCMLD-DP021:001; BCBcMAP01_000024; KBio1_000345; KBio2_001287; KBio2_003855; KBio2_006423; KBio3_001156; DTXSID80992212; NINDS_000345; HMS2090E06; DOXYTETRACYCLINE; DOXYCYCLINE; HY-N0565; LMPK07000001; s5159; ZINC16052277; AKOS015900372; ZINC100056779; ZINC100302137; ZINC100611210; ZINC109562088; CCG-204498; DB00254; MCULE-4368118692; SDCCGSBI-0050391.P005; IDI1_000345; SMP1_000107; NCGC00161602-01; NCGC00161602-03; NCGC00161602-04; NCGC00161602-05; NCGC00161602-14; NCGC00188979-01; (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo-; AS-13499; I455; SBI-0050391.P004; CS-0009105; 1368-EP2269978A2; 1368-EP2269985A2; 1368-EP2269991A2; 1368-EP2284150A2; 1368-EP2284151A2; 1368-EP2284152A2; 1368-EP2284153A2; 1368-EP2284155A2; 1368-EP2284156A2; 1368-EP2284164A2; 1368-EP2287140A2; 1368-EP2287148A2; 1368-EP2287150A2; 1368-EP2289871A1; 1368-EP2295402A2; 1368-EP2295419A2; 1368-EP2298732A1; 1368-EP2301534A1; 1368-EP2301912A2; 1368-EP2301913A1; 1368-EP2301914A1; 1368-EP2301916A2; 1368-EP2305637A2; 1368-EP2305640A2; 1368-EP2308863A1; 1368-EP2311451A1; 1368-EP2311796A1; 1368-EP2311797A1; 1368-EP2311798A1; 1368-EP2311799A1; 1368-EP2316450A1; C06973; D07876; AB00053465-03; AB00053465_04; AB00053465_05; 564D250; Doxycycline, Antibiotic for Culture Media Use Only; Q422442; SR-01000075844-7; W-105517; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid; 7164-70-7
    Click to Show/Hide
Molecular Type
Small molecule
Disease Periodontal disease [ICD-11: DA0C] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
93% of drug becomes completely available to its intended biological destination(s)
Clearance
The clearance of drug is 75 mL/min
Elimination
Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% can be accounted for in the feces
Half-life
The concentration or amount of drug in body reduced by one-half in 16.33 +/- 4.53 hours
Metabolism
The drug is metabolized via the liver
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.4285 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.12%
Vd
The volume of distribution (Vd) of drug is 0.7 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C22H24N2O8
PubChem CID
54671203
Canonical SMILES
CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
InChI
1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
InChIKey
SGKRLCUYIXIAHR-AKNGSSGZSA-N
CAS Number
CAS 564-25-0
ChEBI ID
CHEBI:50845
TTD Drug ID
D0S0LZ
DrugBank ID
DB00254
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Alpha-1 antitrypsin      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model At the age of 10 weeks, DBA/1 mice were immunized intradermally at the base of the tail with 0.1 ml of emulsion containing 100 ug of type II collagen.
                    Experimental
                    Result(s)		 Doxycycline and hAAT in combination also inhibited IL-6 expression from LPS-stimulated NIH/3T3 mouse fibroblast cells, indicating a contributing mechanism of arthritis inhibition.
          Spectinomycin      Legionella pneumophila     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Chlamydia trachomatis strains Microorganism model Chlamydia trachomatis
                    Experimental
                    Result(s)		 A combination of spectinomycin with doxycycline was found to be more effective against Chlamydia trachomatis.
Target and Pathway
Target(s) Bacterial 30S ribosomal RNA (Bact 30S rRNA)  Molecule Info  [4]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6464).
Reference 2 Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med. 2010 Jan;12(1):35-44.
Reference 3 In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother. 2005 Apr;49(4):1584-6.
Reference 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link